- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc stock price live, this page displays NASDAQ CTMX stock exchange data. View the CTMX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the CytomX Therapeutics Inc real time stock price chart below.
What Is the CytomX Therapeutics Inc Stock Price Today?
The CytomX Therapeutics Inc stock price today is 4.560.
What Is the Stock Symbol for CytomX Therapeutics Inc?
The stock ticker symbol for CytomX Therapeutics Inc is CTMX.
Is CTMX the Same as $CTMX?
$CTMX is a common way to refer to the CytomX Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does CytomX Therapeutics Inc Trade On?
CytomX Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is CytomX Therapeutics Inc a Good Stock to Buy?
Determining whether CytomX Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current CytomX Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTMX quote. (ISIN: US23284F1057)
What Is the CytomX Therapeutics Inc Stock Price Today?
The CytomX Therapeutics Inc stock price today is 4.560.
What Is the Stock Symbol for CytomX Therapeutics Inc?
The stock ticker symbol for CytomX Therapeutics Inc is CTMX.
Is CTMX the Same as $CTMX?
$CTMX is a common way to refer to the CytomX Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does CytomX Therapeutics Inc Trade On?
CytomX Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is CytomX Therapeutics Inc a Good Stock to Buy?
Determining whether CytomX Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current CytomX Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTMX quote. (ISIN: US23284F1057)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.390
4.660
52 wk Range
0.610
8.210
Earnings results expected in 15 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.3904.660
52 wk Range
0.6108.210
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CTMX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
13.667
Upside
+199.71%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
CytomX Therapeutics Inc SWOT Analysis
Market Valuation | Analysts maintain an average price target of $3.50, with CytomX's stock near 52-week lows. Explore the potential for revaluation based on upcoming clinical milestones |
Collaborative Edge | Delve into CytomX's partnership with Amgen on CX-904, a bispecific probody showing early promise in pancreatic cancer, with Phase 1 updates expected by end of 2024 |
Financial Fortitude | Despite negative EPS forecasts, CytomX's strategic workforce reduction extends cash runway to Q2 2026, demonstrating prudent resource management amid development |
Pipeline Promise | CytomX's innovative cancer treatments, including EpCAM ADC and Interferon-alpha 2b, are set for crucial data releases in 2025, potentially validating their Probody platform |
CytomX Therapeutics Inc Earnings Call Summary for Q4/2025
- CytomX's lead candidate Varseta-M demonstrated improved progression-free survival in colorectal cancer, driving 48.72% premarket stock surge to $6.96.
- Company plans to initiate registrational studies for Varseta-M in H1 2027, targeting both late-line and early-line CRC treatment markets.
- Management positions Varseta-M as 'company-building asset' with potential for pan-tumor applications beyond colorectal cancer indications.
- Stock delivered 620% return over past year with high volatility (beta 2.48); analysts set $10 price target amid uncertain regulatory timeline.
- No specific financial metrics disclosed; focus remains on clinical advancement and R&D investment for first-in-class Probody ADC technology.
Last Updated: 03/16/2026, 09:13 AM
Read Full TranscriptCytomX Therapeutics Inc investor slides for Q4/2025
Last Update: Mar 16, 2026
See full investor slides
Compare CTMX to Peers and Sector
Metrics to compare | CTMX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCTMXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −48.4x | −10.0x | −0.5x | |
PEG Ratio | 0.34 | −0.30 | 0.00 | |
Price / Book | 10.0x | 4.9x | 2.6x | |
Price / LTM Sales | 12.9x | 26.2x | 3.2x | |
Upside (Analyst Target) | 164.3% | 29.5% | 47.6% | |
Fair Value Upside | Unlock | −6.0% | 6.1% | Unlock |
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.667
(+199.71% Upside)
Earnings
Latest Release
Mar 16, 2026
EPS / Forecast
-0.17 / -0.09
Revenue / Forecast
661K / 9.88M
People Also Watch
FAQ
What Is the CytomX Therapeutics Inc (CTMX) Stock Price Today?
The CytomX Therapeutics Inc stock price today is 4.560 USD.
What Stock Exchange Does CytomX Therapeutics Inc Trade On?
CytomX Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for CytomX Therapeutics Inc?
The stock symbol for CytomX Therapeutics Inc is "CTMX."
What Is the CytomX Therapeutics Inc Market Cap?
As of today, CytomX Therapeutics Inc market cap is 978.200M USD.
What Is CytomX Therapeutics Inc's Earnings Per Share (TTM)?
The CytomX Therapeutics Inc EPS (TTM) is -0.148.
When Is the Next CytomX Therapeutics Inc Earnings Date?
CytomX Therapeutics Inc will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is CTMX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has CytomX Therapeutics Inc Stock Split?
CytomX Therapeutics Inc has split 0 times.
How Many Employees Does CytomX Therapeutics Inc Have?
CytomX Therapeutics Inc has 69 employees.
What is the current trading status of CytomX Therapeutics Inc (CTMX)?
As of Apr 15, 2026, CytomX Therapeutics Inc (CTMX) is trading at a price of 4.560 USD, with a previous close of 4.540 USD. The stock has fluctuated within a day range of 4.390 USD to 4.660 USD, while its 52-week range spans from 0.610 USD to 8.210 USD.
What Is CytomX Therapeutics Inc (CTMX) Price Target According to Analysts?
The average 12-month price target for CytomX Therapeutics Inc is 13.667 USD, with a high estimate of 17 USD and a low estimate of 11 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +199.71% Upside potential.
What Is the CTMX Premarket Price?
CTMX's last pre-market stock price is 4.550 USD. The pre-market share volume is 7,350.000, and the stock has decreased by 0.010, or 0.220%.
What Is the CTMX After Hours Price?
CTMX's last after hours stock price is 4.590 USD, the stock has decreased by 0.030, or 0.660%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.